Study guide

2.5 Purine, Pyrimidine Metabolism & the Porphyrias

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

2.5 Purine, Pyrimidine Metabolism & the Porphyrias

Key Takeaways Explain This Topic AI

Acute intermittent porphyria causes neurovisceral attacks without photosensitivity and is confirmed by raised urinary porphobilinogen during an attack.

Porphyria cutanea tarda is the commonest porphyria, presents with blistering photosensitivity and skin fragility, and is strongly associated with hepatitis C, alcohol and haemochromatosis.

Allopurinol inhibits xanthine oxidase and precipitates life-threatening myelosuppression if co-prescribed with azathioprine or mercaptopurine without dose reduction.

Last updated: September 2026

Note

MRCP Part 1 Blueprint Focus : Inborn errors of metabolism and metabolic biochemistry constitute high-yield questions on the exam. Candidates must distinguish between enzyme deficiencies in purine catabolism, acute vs cutaneous porphyrias, glycogen storage diseases, sphingolipidoses, and amino acid catabolism disorders based on clinical presentation, biochemical markers, and histology.

Purine & Pyrimidine Metabolism: Pathways & Clinical Pathology

Purines (adenine, guanine) and pyrimidines (cytosine, thymine, uracil) are essential for nucleic acid synthesis, energy transfer (ATP, GTP), and intracellular signaling. Purine Salvage and Degradation Pathways

  • AMP IMP GMP
  • │ │ │
  • ▼ ▼ ▼
  • Adenosine Inosine Guanosine
  • │ (Adenosine Deaminase) │ │
  • ▼ ▼ ▼
  • Inosine ──────────────────────────> Hypoxanthine Guanine
  • │ │
  • │ (Xanthine Oxidase) │
  • ▼ ▼
  • Xanthine <───────────────────────────────┘
  • │
  • │ (Xanthine Oxidase)
  • ▼
  • Uric Acid (Excreted in Urine)
  • Purine Salvage versus De Novo Synthesis

Purines can be synthesised de novo from 5-phosphoribosyl-1-pyrophosphate (PRPP) in an energy-costly pathway, or reclaimed from dietary nucleic acids and cellular turnover via the purine salvage pathway:

Hypoxanthine-Guanine Phosphoribosyltransferase (HGPRT) : Converts hypoxanthine to IMP and guanine to GMP, consuming PRPP.

Adenine Phosphoribosyltransferase (APRT) : Converts adenine to AMP, consuming PRPP.

Gout and Hyperuricaemia

Uric acid is the poorly soluble end-product of purine degradation, formed sequentially from hypoxanthine to xanthine, and xanthine to uric acid by xanthine oxidase .

Pathophysiology : Hyperuricaemia (serum urate >420 micromol/L [>7.0 mg/dL]) leads to precipitation of monosodium urate (MSU) crystals in synovial joints and avascular tissues.

Crystal Characteristics : Synovial fluid polarized light microscopy reveals needle-shaped crystals with strong negative birefringence (crystals appear bright yellow when aligned parallel to the slow axis of the red compensator filter, and blue when perpendicular).

Mechanisms : Approximately 90% of gout cases stem from renal underexcretion (reduced glomerular filtration, volume depletion, or drug interference: thiazide diuretics, loop diuretics, ciclosporin, low-dose aspirin, alcohol which generates lactate competing for proximal tubular excretion). Approximately 10% stem from overproduction (myeloproliferative disorders, tumor lysis syndrome, severe psoriasis, PRPP synthetase hyperactivity).

Lesch-Nyhan Syndrome

Genetics : X-linked recessive, total deficiency of HGPRT on Xq28.

Biochemical Pathogenesis : Absent HGPRT prevents hypoxanthine and guanine salvage. Unconsumed PRPP accumulates to supranormal concentrations, acting as an allosteric feed-forward activator of amidophosphoribosyltransferase (the rate-limiting enzyme of de novo purine synthesis). This causes massive, uncontrolled purine synthesis and degradation into uric acid.

Clinical Presentation :

Metabolic / Renal : Severe hyperuricaemia, urate nephrolithiasis, obstructive uropathy, and orange "sand" (sodium urate crystals) noted in infant diapers.

Neurological : Severe extrapyramidal movement disorder: choreoathetosis, dystonia, and spastic cerebral palsy-like motor impairment emerging in the first year (due to basal ganglia dopamine deficiency).

Behavioral : Classic hallmark is compulsive self-mutilation (severe biting of lips, tongue, and fingertips; head-banging) and aggressive outbursts.

Adenosine Deaminase (ADA) Deficiency

Pathophysiology : Autosomal recessive inborn error accounting for ~15-20% of cases of Severe Combined Immunodeficiency (SCID) . ADA normally deaminates adenosine to inosine and deoxyadenosine to deoxyinosine.

Molecular Toxicity : Absent ADA causes massive accumulation of intracellular deoxyadenosine , which is phosphorylated to toxic levels of dATP . Elevated dATP allosterically inhibits ribonucleotide reductase , starving dividing cells of deoxyribonucleotides (dNTPs) and arresting DNA replication. Immature T and B lymphocyte progenitors in the thymus and bone marrow are exquisitely sensitive, undergoing widespread apoptosis.

Clinical Features : Severe, recurrent opportunistic bacterial, viral, and fungal infections (e.g., Pneumocystis jirovecii , disseminated cytomegalovirus, intractable Candida thrush), profound lymphopenia with absent T, B, and NK cells, failure to thrive, and absent thymic shadow on chest radiograph.

The Porphyrias: Neurovisceral Attacks vs Cutaneous Photosensitivity

Porphyrias are inborn errors of the 8-step heme biosynthetic pathway. Heme is synthesized in all nucleated cells, predominantly in erythroid bone marrow (80%, for haemoglobin) and hepatocytes (15-20%, for cytochrome P450 enzymes). Heme Biosynthesis Pathway & Enzymatic Blocks

  • Glycine + Succinyl-CoA
  • │ (ALA Synthase: rate-limiting; ALAS-1 in liver, ALAS-2 in bone marrow)
  • ▼
  • delta-Aminolevulinic Acid (ALA)
  • │ (ALA Dehydratase)
  • ▼
  • Porphobilinogen (PBG)
  • │ (PBG Deaminase / HMB Synthase) ───[Block: Acute Intermittent Porphyria / AIP]
  • ▼
  • Hydroxymethylbilane (HMB)
  • │ (Uroporphyrinogen III Synthase) ──[Block: Congenital Erythropoietic Porphyria / CEP]
  • ▼
  • Uroporphyrinogen III
  • │ (Uroporphyrinogen Decarboxylase) ─[Block: Porphyria Cutanea Tarda / PCT]
  • ▼
  • Coproporphyrinogen III ──> Protoporphyrinogen IX ──> Protoporphyrin IX ──> Heme (via Ferrochelatase)

Feature Acute Intermittent Porphyria (AIP) Porphyria Cutanea Tarda (PCT)

Enzyme Defect Porphobilinogen (PBG) Deaminase (Hydroxymethylbilane synthase) Uroporphyrinogen Decarboxylase (UROD)

Inheritance Autosomal Dominant (~10-20% penetrance) 80% Acquired / Sporadic; 20% Familial (AD)

Accumulated Precursors delta-Aminolevulinic acid (ALA) & Porphobilinogen (PBG) Uroporphyrinogen (oxidised to uroporphyrin)

Cutaneous Photosensitivity ABSENT (block occurs prior to porphyrin ring formation) PRESENT (blisters, skin fragility, milia, hypertrichosis)

Neurovisceral Attacks PRESENT (severe abdominal pain, neuropathy, psychosis) ABSENT

Urine Characteristics Darkens to port-wine / red-brown upon standing in light/air Red-brown / tea-colored; coral-pink fluorescence under Wood's lamp

Precipitating Triggers CYP450 inducers, fasting/caloric restriction, hormonal fluctuations Alcohol, Hepatitis C virus (HCV), iron overload (haemochromatosis), oestrogen

Definitive Treatment IV Hemin (hematin), high-dose IV glucose/dextrose Repeated therapeutic phlebotomy, low-dose chloroquine/hydroxychloroquine

Acute Intermittent Porphyria (AIP)

Pathophysiology : Partial (~50%) deficiency of PBG deaminase . Symptoms are triggered when hepatic ALAS-1 is induced. Fasting (via PGC-1alpha induction) or CYP-inducing drugs (which consume free hepatic heme, relieving feedback repression on ALAS-1) trigger a massive influx of precursors into the pathway, accumulating neurotoxic ALA and PBG .

Clinical Manifestations (The 5 "P"s) :

Painful abdomen : Severe, diffuse, poorly localized, colicky pain out of proportion to physical signs (soft, non-tender abdomen).

Polyneuropathy : Motor-predominant axonal peripheral neuropathy, typically starting with proximal upper limb weakness (wrist drop, shoulder girdle paresis), which can progress to quadriplegia and diaphragmatic respiratory paralysis.

Psychiatric manifestations : Confusion, anxiety, psychosis, visual hallucinations, and agitation.

Port-wine urine : Colorless when freshly voided; PBG polymerizes to porphobilin upon light/air exposure, turning urine deep red/brown/black.

Precipitated by drugs : Barbiturates, carbamazepine, phenytoin, rifampicin, sulphonamides, nitrofurantoin, alcohol, low-calorie diets, and cyclical progesterone in the luteal phase of the menstrual cycle.

Autonomic instability (sinus tachycardia, hypertension) and hyponatraemia (due to SIADH or vomiting) are frequent.

Diagnosis : Markedly elevated urinary PBG (quantitative ion-exchange chromatography) during an acute attack.

Management : Immediate cessation of porphyrinogenic medications. Administer IV Hemin (hematin) , which reconstitutes the hepatic heme pool, directly suppressing ALAS-1 transcription. Administer high-dose intravenous dextrose (300 g/day) , which suppresses ALAS-1 via insulin-mediated FoxA2/PGC-1alpha downregulation.

Porphyria Cutanea Tarda (PCT)

Pathophysiology : Deficiency of uroporphyrinogen decarboxylase (UROD) . Uroporphyrinogen accumulates in the liver and circulates to the dermis. The conjugated tetrapyrrole rings absorb long-wave ultraviolet A light (Soret band ~400-410 nm), generating singlet oxygen and reactive radicals that damage capillary basement membranes.

Clinical Features : Chronic blistering on sun-exposed sites (dorsa of hands, forearms, face). Fragile skin that sloughs with minor friction, producing weeping erosions, atrophic scarring, and milia (tiny subepidermal keratin cysts). Facial hypertrichosis (temporal/malar hair growth) and hyperpigmentation. Tea-colored urine that fluoresces coral-pink under Wood's lamp (365 nm UVA) .

Associations : Strongly linked with Hepatitis C virus (HCV) infection , hepatic iron overload ( HFE C282Y mutations), chronic alcohol abuse, and exogenous oestrogens.

Management : Serial venesection (therapeutic phlebotomy) to deplete hepatic iron stores (target ferritin <50 micrograms/L), restoring UROD activity. Low-dose oral chloroquine or hydroxychloroquine (100 mg twice weekly) forms water-soluble complexes with porphyrins, enhancing renal clearance. Direct-acting antivirals for HCV.